Safety and immunogenicity of influenza A H1N1 vaccines

Expert Review of Vaccines

Volumn 9, Issue 4, 2010, Pages 365-369

  Lu, Wei ^a   Tambyah, Paul A ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Hemagglutination inhibition; Influenza A H1N1; Seroprotection; Split virion; Vaccine immunogenecity; Whole virion

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; OSELTAMIVIR; SIALIDASE INHIBITOR; THIOMERSAL; ZANAMIVIR;

ANTIBODY TITER; ANTIVIRAL SUSCEPTIBILITY; CHEMOPROPHYLAXIS; CHINA; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ECONOMIC ASPECT; FEVER; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; INJECTION SITE PAIN; INJECTION SITE PRURITUS; MASS IMMUNIZATION; MEXICO; MORBIDITY; MORTALITY; MYALGIA; NAUSEA; NOTE; PANDEMIC; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEROLOGY; SINGLE DRUG DOSE; SWINE; VACCINE PRODUCTION; VALIDITY; VIRION; VIRUS IMMUNITY; VIRUS STRAIN;

EID: 77950610590     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.23     Document Type: Note

References (21)

1. Liang XF, Wang HQ, Wang JZ et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 375, 56-66 (2010).
2. CDC. Swine influenza A (H1N1) infection in two children - southern California, March-April 2009. MMWR Morb. Mortal. Wkly Rep. 58, 400-402 (2009).
3. CDC. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb. Mortal. Wkly Rep. 58, 521-524 (2009).
4. CDC. Effectiveness of 2008-2009 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) - United States, May-June 2009. MMWR Morb. Mortal. Wkly Rep. 58, 1241-1245 (2009).
5. Hancock K, Veguilla V, Lu X et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med. 361, 1945-1952 (2009).
6. CDC. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis - North Carolina, 2009. MMWR Morb. Mortal. Wkly Rep. 58, 969-972 (2009).
7. Wood JM. Selection of influenza vaccine strains and developing pandemic vaccines. Vaccine 20(Suppl. 5), B40-B44 (2002).
8. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354, 1343-1351 (2006).
9. Bresson JL, Perronne C, Launary O et al. Safety and immunogenicity of an inactivated split-virion influenza A/ Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet 367, 1657-1664 (2006).
10. Lin J, Zhang J, Dong X et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a Phase I randomised controlled trial. Lancet 368, 991-997 (2006).
11. Ehrlich HJ, Müller M, Oh HM et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 358, 2573-2584 (2008).
12. Chen H, Wang Y, Liu W et al. Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China. Emerg. Infect. Dis. 15, 1849-1850 (2009).
13. Plennevaux E, Sheldon E, Blatter M et al. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled Phase 2 trials. Lancet 375, 41-48 (2010).
14. Vajo Z, Tamas F, Sinka L, Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-2010 influenza season: a multicentre, randomised controlled trial. Lancet 375, 49-55 (2010).
15. Baldo V, Baldovin T, Floreani A et al. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine 25, 3955-3961 (2007).
16. Greenberg ME, Lai MH, Hartel GF et al. Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. N. Engl. J. Med. 361, 2405-2413 (2009).
17. Zhu FC, Wang H, Fang HH et al. A novel influenza A (H1N1) vaccine in various age groups. N. Engl. J. Med. 361, 2414-2423 (2009).
18. McConnell J. Influenza in the Asia Pacific. Lancet Infect. Dis. 9, 590-591 (2009).
19. Sui J, Hwang WC, Perez S et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16, 265-273 (2009).
20. Li OT, Poon LL. One step closer to universal influenza epitopes. Expert Rev. Anti Infect Ther. 6, 687-690 (2009).
21. Kim JH, Jacob J. DNA vaccines against influenza viruses. Curr. Top. Microbiol. Immunol. 333, 197-210 (2009).